Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1189 results
July 2015
-
Press Release
Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd
Novartis is spinning off three mid stage clinical assets to Mereo for further development in exchange for equity Novartis will have a stake in the success of the development of these compounds… -
Press Release
Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt
Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees New trustees also include Professor Peter Piot of the London School… -
Press Release
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable[1] Basal cell carcinoma, the most common form of skin… -
Press Release
Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones
CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for… -
Press Release
Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder
If approved, Revolade would be the first treatment option in its class in the EU for certain patients with SAA Approximately 40% of SAA patients unresponsive to initial immunosuppressive… -
Press Release
Novartis: solide performance au deuxième trimestre grâce à la force de l'innovation et aux progrès des nouveaux lancements
Croissance des ventes, du résultat opérationnel core[1] et du BPA core (tcc[1]) des activités poursuivies[2] au T2: Le chiffre d'affaires net s'est élevé à USD 12,7 milliards (-5%, +6% tcc). Le… -
Press Release
Novartis erzielt im zweiten Quartal eine solide Performance mit starken Innovationen und Fortschritten bei Neueinführungen
Die fortzuführenden Geschäftsbereiche[2] steigern im zweiten Quartal den Umsatz, das operative Kernergebnis[1] und den Kerngewinn pro Aktie (kWk[1]): Der Nettoumsatz beläuft sich auf USD 12,7… -
Press Release
Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3… -
Press Release
Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
WHO prequalified Coartem® 80/480mg is the first and only high strength malaria treatment available for donor-funded public sector procurement Coartem® 80/480mg reduces the pill burden for… -
Press Release
Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization
First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment… -
Press Release
Alcon receives European Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps to maintain the integrity of the incision while facilitating smooth, consistent delivery of the IOL…